Naglazyme market seen growing through 2030 on rare disease demand
The Business Research Company says the Naglazyme market is set for steady growth through 2030, driven by rising rare disease diagnosis, personalized medicine, and higher healthcare spending. North America led the market in 2025, while the report points to broader global opportunities as enzyme replacement therapy adoption expands.
Why it matters: - The Naglazyme market sits inside a broader rare disease treatment market that is being shaped by earlier diagnosis, more orphan-drug support, and wider access to specialty care. - Growth in this market matters for patients with mucopolysaccharidosis VI, where Naglazyme is used to help manage symptoms and improve quality of life. - The forecast period to 2030 points to continued demand for enzyme replacement therapies as rare disease care becomes more specialized and more widely available.
What happened: - The Business Research Company released a market segmentation analysis on Naglazyme and said the market has been evolving steadily. - The report said the market outlook through 2030 is supported by advances in rare disease diagnosis and treatment, along with growing awareness. - The report identified North America as the largest regional market in 2025. - The analysis also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.
The details: - Naglazyme, or galsulfase, is an enzyme replacement therapy for mucopolysaccharidosis VI, also known as Maroteaux-Lamy syndrome. - The therapy supplements the missing or deficient enzyme that helps break down glycosaminoglycans, or GAGs. - Naglazyme is typically given by intravenous infusion under the supervision of healthcare professionals experienced in MPS disorders. - Historical growth has been linked to better diagnosis of lysosomal storage disorders, rare disease awareness campaigns, orphan-drug approvals, expanded access to specialized treatment centers, and early clinical validation of enzyme replacement therapies. - The report said future growth is likely to come from more investment in rare disease research, stronger demand for durable therapies, broader use of personalized medicine, greater government support for orphan drugs, and better biologic manufacturing. - The report highlighted wider adoption of enzyme replacement therapies, greater focus on access, more infusion-based treatment, stronger long-term disease management, and more patient-centered care as key trends. - The report said rising rare genetic disorder incidence is helping the market expand. - In October 2024, the Cystic Fibrosis Trust reported that registered cystic fibrosis patients in the UK increased from 11,148 in 2022 to 11,318 in 2023, a 1.5% year-over-year increase. - Personalized medicine is also supporting market growth by tailoring treatment to a patient’s genetic makeup, lifestyle and environment. - In February 2024, the Personalized Medicine Coalition said the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. - Higher healthcare spending is another growth driver because it helps fund the development, distribution and availability of specialized treatments. - In May 2024, the UK Office for National Statistics reported healthcare spending rose 5.6% from 2022 to 2023 to about $317.63 billion, or £292 billion, in 2023. - The report also listed expanded 2026 market-report features, including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, key technology analysis and updated visuals. - The Business Research Company provided contact details for experts, including Saumya Sahay and Oliver Guirdham, plus email, phone numbers and social links.
Between the lines: - The report is less about Naglazyme alone and more about the economics of rare disease care, where diagnosis rates, reimbursement, specialty infrastructure and biologics manufacturing all affect uptake. - The emphasis on personalized medicine suggests the market may benefit from more targeted treatment pathways, even though Naglazyme remains a standardized enzyme replacement therapy. - North America’s lead indicates the strongest demand and access conditions are still concentrated in mature healthcare markets.
What's next: - The market is expected to continue expanding through 2030 if rare disease diagnosis, government support and specialty treatment access keep improving. - More biologic manufacturing capacity and broader use of infusion-based care could shape how quickly access improves across regions. - The report points to ongoing opportunity in regions beyond North America as rare disease treatment infrastructure develops.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
United Kingdom Political Times
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.